Factor Model (net +1.5)
Factor Model
net +1.5 3.2 / 10Immunic raises $400M for Phase 3 MS program completion
Watch: Topline Phase 3 ENSURE data due end of 2026 is the pivotal catalyst. Hit the primary endpoint with statistical significance and the path to mid-2027 NDA submission is locked. Miss and the stock reprices sharply — MS is a competitive space and efficacy gaps kill pipeline assets fast.
Immunic secured up to $400 million in private placement financing, with $200 million received immediately, to fund the completion of Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis and preparation for commercial launch. The twin studies enrolled 2,200 patients and an independent data monitoring committee in 2024 recommended the trials continue without modification. Topline data from Phase 3 is expected at the end of 2026, with an NDA submission targeted for mid-2027.
This funding windfall eliminates near-term cash concerns and de-risks the clinical timeline through NDA submission. A successful Phase 3 readout in a 2,200-patient program with unmodified trial continuation signals strong efficacy signals — this sets up a potential regulatory win in MS, a sizable chronic disease market where approved competitors exist but demand outpaces supply.
Evidence
3 older signals
Fundamentals & Data ▾
Recent transactions
Get alerted when IMUX changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.